Difference analysis of myeloid leukemia fusion oncogene expression network based on time series

WANG Hui-hui; SA Jian; CAO Hong-yan; CUI Yue-hua

doi:10.16462/j.cnki.zhjbkz.2020.03.006

Volume 24 Issue 3

Jun. 2020

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2020 > 24(3): 274-278

WANG Hui-hui, SA Jian, CAO Hong-yan, CUI Yue-hua. Difference analysis of myeloid leukemia fusion oncogene expression network based on time series[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(3): 274-278. doi: 10.16462/j.cnki.zhjbkz.2020.03.006

Citation:

WANG Hui-hui, SA Jian, CAO Hong-yan, CUI Yue-hua. Difference analysis of myeloid leukemia fusion oncogene expression network based on time series[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(3): 274-278. doi: 10.16462/j.cnki.zhjbkz.2020.03.006

Citation:

PDF( 4348 KB)

Difference analysis of myeloid leukemia fusion oncogene expression network based on time series

doi: 10.16462/j.cnki.zhjbkz.2020.03.006

WANG Hui-hui¹,
SA Jian^{1, 2},
CAO Hong-yan^{1, 2
,
,},
CUI Yue-hua^{3
,
,}

1.
Department of Health Statistics, Shanxi Medical University, Taiyuan 030001, China
2.
Shanxi Provincial Key Laboratory of Major Diseases Risk Assessment, Taiyuan 030001, China
3.
Department of Statistics and Probability, Michigan State University, East Lansing, MI 48824, USA

Funds: National Natural Science Foundation of China(71403156); Shanxi Scholarship Council of China(2017-054); Applied Basic Research Program of Shanxi Province(201901D111204)

More Information

Corresponding author: CAO Hong-yan,E-mail:cao_hong_yan@163.com; CUI Yue-hua,E-mail:cui@stt.msu.edu
Received Date: 2019-09-30
Rev Recd Date: 2019-12-20
Publish Date: 2020-03-10

Abstract

Abstract

Objective Focusing on four types acute myeloid leukemia(AML)fusion oncogenes, so as to explore the network difference with time series expression data and further identify important genes in networks. Methods Gene network difference analysis was conducted while focusing on the global attributes of the union network. The CompNet neighborhood similarity index(CNSI) was adopted to assess network similarity. "fast-greedy" algorithm was used to detect communities based on the union network, and further identify hub genes. Results The CNSI value between NUP98-HOXA9-3 d and NUP98-HOXA9-8 d was 0.73, while AML1-ETO-6 h and PML-RARA-6 h was 0.25. We identified ten AML associated genes and seven of them(TNF, VEGFA, EP300, EGF, CD44, PTGS2, SMAD3) were reported in the literature. Conclusions The network difference analysis revealed the pattern and heterogeneity of AML gene expression change across different time points, and further provided target genes for efficient treatment of AML with different types of fusion oncogenes.
- AML,
- Fusion oncogene,
- Hub gene,
- Network difference analysis,
- Time series gene expression data

FullText(HTML)

References(33)

References

[1]	National Cancer Institute(NIH). Adult acute myeloid leukemia treatment-national cancer institute[M]. Bethesda: National Cancer Institute(US), 2013.
[2]	Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia[J]. N Engl J Med, 2015, 373(12): 1136-1152. DOI: 10.1056/NEJMra1406184.
[3]	Zhang H, Song G, Song G, et al. Identification of DNA methylation prognostic signature of acute myelocytic leukemia[J]. PloS one, 2018, 13(6): e0199689. DOI: 10.1371/journal.pone.0199689.
[4]	Crispino JD, Horwitz MS. GATA factor mutations in hematologic disease[J]. Blood, 2017, 129(15): 2103-2110. DOI: 10.1182/blood-2016-09-687889.
[5]	Hirabayashi S, Wlodarski MW, Kozyra E, et al. Heterogeneity of GATA2-related myeloid neoplasms[J]. Int J Hematol, 2017, 106(2): 175-182. DOI: 10.1007/s12185-017-2285-2.
[6]	李川, 梁佩淇, 刘卓刚, 等. AML1-ETO融合基因转阴对急性髓细胞白血病预后的影响[J].现代肿瘤医学, 2018, 26(19): 3106-3110. DOI: 10.3969/j.issn.1672-4992.2018.19.028. Li C, Liang PQ, Liu ZG, et al. The effect of AML1-ETO fusion gene switched on the prognosis of patients in acute myeloid leukemia[J]. Modern Oncology, 2018, 26(19): 3106-3110. DOI: 10.3969/j.issn.1672-4992.2018.19.028.
[7]	Lee JH, Lee JH. Seven co-occurring mutations in a patient with acute myeloid leukemia identified by next-generation sequencing[J]. Clin Lab, 2019, 65(6). DOI: 10.7754/Clin.Lab.2018.181223.
[8]	Iijima-Yamashita Y, Matsuo H. Multiplex fusion gene testing in pediatric acute myeloid leukemia[J]. Pediatr Int, 2018, 60(1): 47-51. DOI: 10.1111/ped.13451.
[9]	林凡琳, 潘慧, 刘胜先, 等.急性髓系白血病发病机制的研究进展[J].中国细胞生物学学报, 2018, 40(5): 850-856. DOI: 10.11844/cjcb.2018.05.0319. Lin FL, Pan H, Liu SX, et al. Advances in the pathogenesis study of acute myeloid leukemia[J]. Chinese Journal of Cell Biology. 2018, 40(5): 850-856. DOI: 10.11844/cjcb.2018.05.0319.
[10]	刘会娟, 侯艳, 李康. ARTIVA在时间序列基因表达数据网络构建中的应用[J].中国卫生统计, 2018, 35(5): 642-645. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgwstj201805001 Liu HJ, Hou Y, Li K. The application of auto regressive time varying models to the network building of time series microarray data[J]. Chin J Health Statistics, 2018, 35(5): 642-645. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgwstj201805001
[11]	刘秉慈, 郑玉新.基因组学、蛋白质组学及其在预防医学中的应用[J].中华预防医学杂志, 2004, 38(2): 130-134. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyfyx200402020 Liu BC, Zheng YX. Genomics, proteomics and their applications in preventive medicine[J]. Chin J Prev Med, 2004, 38(2): 130-134. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyfyx200402020
[12]	Storey JD, Wenzhong X, Leek JT, et al. Significance analysis of time course microarray experiments[J]. Proc Natl Acad Sci U S A, 2005, 102(36): 12837-12842. DOI: 10.1073/pnas.0504609102.
[13]	Bringmann LF, Nathalie V, Marieke W, et al. A network approach to psychopathology: new insights into clinical longitudinal data[J]. PloS one, 2013, 8(4): e60188. DOI: 10.1371/journal.pone.0060188.
[14]	Kuntal BK, Dutta A, Mande SS. CompNet: a GUI based tool for comparison of multiple biological interaction networks[J]. BMC bioinformatics, 2016, 17(1): 185. DOI: 10.1186/s12859-016-1013-x.
[15]	Abdul-Nabi AM, Yassin ER, Varghese N, et al. In vitro transformation of primary human CD34⁺ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML[J]. PloS one, 2010, 5(8): e12464. DOI: 10.1371/journal.pone.0012464.
[16]	Abos A, Segura B, Baggio HC, et al. Disrupted structural connectivity of fronto-deep gray matter pathways in progressive supranuclear palsy[J]. Neuroimage Clin, 2019, 23: 101899. DOI: 10.1016/j.nicl.2019.101899.
[17]	Leclerc RD. Survival of the sparsest: robust gene networks are parsimonious[J]. Mol Syst Biol, 2008, 4: 213. DOI: 10.1038/msb.2008.52.
[18]	Wang Y, Tao F, Zuo C, et al. Disrupted resting frontal-parietal attention network topology is associated with a clinical measure in children with attention-deficit/hyperactivity disorder[J]. Front psychiatry, 2019, 10: 300. DOI: 10.3389/fpsyt.2019.00300.
[19]	Clauset A, Newman ME, Moore C. Finding community structure in very large networks[J]. Phys Rev E Stat Nonlin Soft Matter Phys, 2004, 70(6 Pt 2): 066111. DOI: 10.1103/physreve.70.066111.
[20]	Liu W, Huang X, Liang X, et al. Identification of key modules and hub genes of Keloids with weighted gene coexpression network analysis[J]. Plast Reconstr Surg, 2017, 139(2): 376-390. DOI: 10.1097/PRS.0000000000003014.
[21]	Maere S, Heymans K, Kuiper M. BiNGO: a cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks[J]. Bioinformatics, 2005, 21(16): 3448-3449. DOI: 10.1002/pssc.200778445.
[22]	Scardoni G, Laudanna C. Centralities based analysis of complex networks[C]. New Frontiers in Graph Theory, 2012: 323-348. DOI: 10.5772/35846.
[23]	Pavlopoulos GA, Secrier M, Moschopoulos CN, et al. Using graph theory to analyze biological networks[J]. BioData Min, 2011, 4(1): 10. DOI: 10.1186/1756-0381-4-10.
[24]	Jain A, Tiwari A, Verma A, et al. Vitamins for cancer prevention and treatment: An insight[J]. Curr Mol Med, 2017, 17(5): 321-340. DOI: 10.2174/1566524018666171205113329.
[25]	Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology[J]. Cell, 2001, 104(4): 487-501. DOI: 10.1016/S0092-8674(01)00237-9.
[26]	Old LJ. Tumor necrosis factor(TNF)[J]. Science(New York), 1985, 230(4726): 630-632. DOI: 10.1126/science.2413547.
[27]	Ferrara N. VEGF: an update on biological and therapeutic aspects[J]. Curr Opin Biotechnol, 2000, 11(6): 617-624. DOI: 10.1016/S0958-1669(00)00153-1.
[28]	Park DJ, Seo AN, Yoon C, et al. Serum VEGF-A and tumor vessel VEGFR-2 levels predict survival in Caucasian but not Asian patients undergoing resection for gastric adenocarcinoma[J]. Ann Surg Oncol, 2015, 22(3): 1508-1515. DOI: 10.1245/s10434-015-4790-y.
[29]	Gayther SA, Batley SJ, Linger L, et al. Mutations truncating the EP300 acetylase in human cancers[J]. Nat Genet, 2000, 24(3): 300-303. DOI: 10.1038/73536.
[30]	Zhao Y, Adjei AA. The clinical development of MEK inhibitors[J]. Nat Rev Clin Oncol, 2014, 11(7): 385-400. DOI: 10.1038/nrclinonc.2014.83.
[31]	Neill T, Schaefer L, Iozzo RV. Decorin: a guardian from the matrix[J]. Am J Pathol, 2012, 181(2): 380-387. DOI: 10.1016/j.ajpath.2012.04.029.
[32]	Lee S, Chung YH, Lee C. US28, a virally-encoded GPCR as an antiviral target for human cytomegalovirus infection[J]. Biomol Ther(Seoul), 2017, 25(1): 69-79. DOI: 10.4062/biomolther.2016.208.
[33]	Qian Z, Zhang Q, Hu Y, et al. Investigating the mechanism by which SMAD3 induces PAX6 transcription to promote the development of non-small cell lung cancer[J]. Respir Res, 2018, 19(1): 262. DOI: 10.1186/s12931-018-0948-z.